Placental function studies in low birth weight infants with and without dysmaturity

Area of Science:

• Reproductive biology
• Maternal-fetal medicine
• Biochemical markers

Background:

• Fetal growth restriction (FGR) affects placental function.
• Distinguishing between FGR infants who are small but healthy and those with dysmaturity is clinically important.
• Placental lactogen (hPL) and pregnancy-specific beta-1 glycoprotein (SP1) are key placental hormones.

Purpose of the Study:

• To evaluate the utility of maternal serum hPL and SP1 levels in differentiating between clinically dysmature and small-for-gestational-age (SGA) infants.
• To assess if these biochemical markers reflect dynamic placental function.

Main Methods:

• Maternal serum concentrations of hPL and SP1 were measured in 51 women who delivered FGR infants.
• Infants were categorized into two groups: clinically dysmature (n=27) and small but normal appearance (n=24).
• Comparison of hormone levels between the two infant groups.

Main Results:

• Maternal hPL and SP1 levels were significantly lower in infants with clinical dysmaturity compared to those who were small but normally appearing.
• Abnormal hPL concentrations (less than 4 mg/L) were found in 44% of dysmature infants, but in none of the small-for-gestational-age infants.
• These findings suggest that the tested biochemical markers are sensitive to placental functional status.

Conclusions:

• Maternal serum hPL and SP1 levels can serve as indicators of placental function in pregnancies complicated by FGR.
• Biochemical testing provides insights into the dynamic aspects of placental function, beyond just fetal size.
• These markers may aid in identifying infants at risk for complications related to placental insufficiency.